These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 8806592)

  • 21. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
    Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
    J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NDF/heregulin stimulates the phosphorylation of Her3/erbB3.
    Kita YA; Barff J; Luo Y; Wen D; Brankow D; Hu S; Liu N; Prigent SA; Gullick WJ; Nicolson M
    FEBS Lett; 1994 Jul; 349(1):139-43. PubMed ID: 8045292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bioactive synthetic peptide of NDF/heregulin.
    Kita Y; Mayer J; Zamborelli T; Hara S; Rohde M; Watson E; Koski R; Ratzkin B; Nicolson M
    Biochem Biophys Res Commun; 1995 May; 210(2):441-51. PubMed ID: 7755620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).
    Jay JI; Brunhoeber PS; Smith MH; Williams RR; Sugarman MC; Free HL; Tast DE
    Histopathology; 2013 Mar; 62(4):563-77. PubMed ID: 23432624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation and characterization of new HER2 monoclonal antibodies.
    Vasconcellos FA; Aleixo PB; Stone SC; Conceição FR; Dellagostin OA; Aleixo JA
    Acta Histochem; 2013 Apr; 115(3):240-4. PubMed ID: 22901624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4).
    Broughton MN; Westgaard A; Paus E; Øijordsbakken M; Henanger KJ; Naume B; Bjøro T
    Tumour Biol; 2017 Jun; 39(6):1010428317707436. PubMed ID: 28653892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. H
    Itai S; Fujii Y; Kaneko MK; Yamada S; Nakamura T; Yanaka M; Saidoh N; Chang YW; Handa S; Takahashi M; Suzuki H; Harada H; Kato Y
    Monoclon Antib Immunodiagn Immunother; 2017 Aug; 36(4):143-148. PubMed ID: 28700270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
    Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
    Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
    Bast RC; Xu F; Yu Y; Crews J; Argon Y; Maier L; Lidor Y; Berchuck A; Boyer CM
    Immunol Ser; 1994; 61():23-30. PubMed ID: 7912111
    [No Abstract]   [Full Text] [Related]  

  • 30. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies.
    Hassani D; Jeddi-Tehrani M; Yousefi P; Mansouri-Fard S; Mobini M; Ahmadi-Zare H; Golsaz-Shirazi F; Amiri MM; Shokri F
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):347-361. PubMed ID: 35079876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of Recombinant Monoclonal Antibodies from Transgenic Chicken Bioreactors in Enzyme-Linked Immunosorbent Assay.
    Mukae T; Yoshii K; Oishi I
    Biol Pharm Bull; 2024; 47(9):1532-1541. PubMed ID: 39313389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis.
    Ben-Kasus T; Schechter B; Lavi S; Yarden Y; Sela M
    Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3294-9. PubMed ID: 19218427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of Neu differentiation factor with the extracellular domain of Her2 and Her3.
    Horan T; Wen J; Arakawa T; Liu N; Brankow D; Hu S; Ratzkin B; Philo JS
    J Biol Chem; 1995 Oct; 270(41):24604-8. PubMed ID: 7592681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling.
    Yip YL; Novotny J; Edwards M; Ward RL
    Int J Cancer; 2003 Apr; 104(3):303-9. PubMed ID: 12569553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.
    Baron AT; Huntley BK; Lafky JM; Reiter JL; Liebenow J; McCormick DJ; Ziesmer SC; Roche PC; Maihle NJ
    Hybridoma; 1997 Jun; 16(3):259-71. PubMed ID: 9219036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification.
    Tagliabue E; Centis F; Campiglio M; Mastroianni A; Martignone S; Pellegrini R; Casalini P; Lanzi C; Ménard S; Colnaghi MI
    Int J Cancer; 1991 Apr; 47(6):933-7. PubMed ID: 1672668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VERO stable cell lines expressing full-length human epidermal growth factor receptors 2 and 3: platforms for subtractive phage display.
    Hedayatizadeh-Omran A; Valadan R; Rafiei A; Tehrani M; Alizadeh-Navaei R
    DNA Cell Biol; 2015 Sep; 34(9):573-8. PubMed ID: 26121156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies.
    Schrohl AS; Pedersen HC; Jensen SS; Nielsen SL; Brünner N
    Histopathology; 2011 Nov; 59(5):975-83. PubMed ID: 22092409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2.
    Szymanska M; Fosdahl AM; Nikolaysen F; Pedersen MW; Grandal MM; Stang E; Bertelsen V
    J Cell Mol Med; 2016 Oct; 20(10):1999-2011. PubMed ID: 27469139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency.
    Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI
    Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.